Sage Rhino Capital LLC Sells 5,258 Shares of Astrazeneca Plc $AZN

Sage Rhino Capital LLC lowered its stake in shares of Astrazeneca Plc (NYSE:AZN) by 49.3% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 5,416 shares of the company’s stock after selling 5,258 shares during the period. Sage Rhino Capital LLC’s holdings in Astrazeneca were worth $1,068,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Kiley Juergens Wealth Management LLC bought a new stake in Astrazeneca during the first quarter worth $394,000. PUREfi Wealth LLC bought a new stake in shares of Astrazeneca in the 1st quarter valued at about $252,000. Collaborative Fund Advisors LLC bought a new stake in shares of Astrazeneca in the 1st quarter valued at about $294,000. Abel Hall LLC lifted its stake in Astrazeneca by 3.9% in the 1st quarter. Abel Hall LLC now owns 6,671 shares of the company’s stock valued at $1,316,000 after purchasing an additional 253 shares during the last quarter. Finally, DGS Capital Management LLC bought a new position in Astrazeneca during the first quarter worth about $252,000. 20.35% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on AZN. Barclays reaffirmed a “buy” rating on shares of Astrazeneca in a research report on Monday, June 1st. TD Cowen reaffirmed a “buy” rating on shares of Astrazeneca in a research report on Wednesday, March 18th. DZ Bank raised shares of Astrazeneca from a “neutral” rating to a “buy” rating in a research report on Wednesday, April 29th. Morgan Stanley reaffirmed an “overweight” rating on shares of Astrazeneca in a report on Wednesday, April 8th. Finally, Jefferies Financial Group reissued a “buy” rating on shares of Astrazeneca in a report on Friday, June 26th. Fourteen equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $205.33.

Astrazeneca Stock Up 1.3%

NYSE AZN traded up $2.49 on Tuesday, hitting $192.65. 478,793 shares of the company were exchanged, compared to its average volume of 2,478,874. The company has a current ratio of 0.91, a quick ratio of 0.71 and a debt-to-equity ratio of 0.52. The company has a market cap of $298.79 billion, a PE ratio of 28.97, a PEG ratio of 1.58 and a beta of 0.24. The stock has a fifty day moving average of $183.97 and a 200-day moving average of $188.38. Astrazeneca Plc has a 12 month low of $137.23 and a 12 month high of $212.71.

Astrazeneca (NYSE:AZN) last posted its quarterly earnings results on Wednesday, April 29th. The company reported $2.58 earnings per share for the quarter, beating the consensus estimate of $2.52 by $0.06. The firm had revenue of $15.29 billion during the quarter, compared to the consensus estimate of $14.93 billion. Astrazeneca had a net margin of 17.19% and a return on equity of 30.86%. As a group, analysts forecast that Astrazeneca Plc will post 10.28 earnings per share for the current year.

Astrazeneca Company Profile

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.